Abstract:Importance: The degree to which health and economic outcomes of musculoskeletal disorders are attributable to high body mass index (BMI) has not been quantified on a global scale. Objective: To estimate global health and economic outcomes associated with musculoskeletal disorders-low back pain (LBP), gout, and osteoarthritis attributable to high BMI in 2019. Design, setting, and participants: This cross-sectional study used data of 192 countries and territories from the Global Burden of Diseases, Injuries, and Risk Factors Study, World Health Organization Global Health Expenditure, World Bank, and International Labour Organization databases. Data analyses were conducted from February 24 to June 16, 2022. Main outcomes and measures: Prevalence, years lived with disability (YLDs), health care costs, and productivity losses due to morbidity from LBP, gout, and osteoarthritis attributable to high BMI by region and country. Prevalence and YLDs were calculated with the population attributable fraction approach. The economic burden, including health care costs and productivity losses due to morbidity, was also quantified. Health care costs borne by the public, private, and out-of-pocket sectors were estimated based on their corresponding payment shares. Productivity losses were estimated based on the output per worker. A sensitivity analysis was conducted to arrive at the base, minimum, and maximum estimates (ie, uncertainty interval [UI]) by using the mean, lower, and upper bounds of all input variables. Results: High BMI was estimated to be responsible for 36.3 million (UI, 18.4-61.0 million), 16.9 million (UI, 7.5-32.5 million), and 73.0 million (UI, 32.4-131.1 million) prevalent cases of LBP, gout, and osteoarthritis, respectively, which accounted for 7.3 million (UI, 3.0-15.0 million) YLDs across 192 countries and territories in 2019. Globally, the YLDs of musculoskeletal disorders attributable to high BMI accounted for 1.0% of all-cause YLDs in the working-age population aged 15 to 84 years. The global total costs of musculoskeletal disorders attributable to high BMI reached $180.7 billion (UI, $83.8-$333.1 billion), including $60.5 billion (UI, $30.7-$100.5 billion) in health care costs and $120.2 billion (UI, $53.1-$232.7 billion) in productivity losses. In terms of the global health care costs, 58.9% ($35.6 billion; UI, $17.8-$59.6 billion) was borne by the public sector, 24.0% ($14.5 billion; UI, $7.8-$23.2 billion) by the private sector, and 17.1% ($10.3 billion; UI, $5.1-$17.6 billion) by the out-of-pocket sector. On average, the total costs accounted for 0.2% of global gross domestic product. Great inequalities in the disease and economic burden existed across regions and countries. Nearly 80% of global health care (82.4%) and morbidity-related costs (82.9%) were paid by high-income countries, whereas more than 60% (61.4%) of global YLDs occurred in middle-income countries. Conclusions and relevance: In this cross-sectional study of 192 countries and territories, a substantial amount of the health and economic impact of musculoskeletal disorders was attributable to high BMI. Developing effective policies and active participation from health professionals to prevent excessive weight gain are needed. More available estimates are also needed to facilitate a global analysis.

Health Effects of Overweight and Obesity in 195 Countries.

Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity

Global Trend in Overweight and Obesity and Its Association with Cardiovascular Disease Incidence.

Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021

Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults During 1980-2013: A Systematic Analysis for the Global Burden of Disease Study 2013

Global health impacts of high BMI: A 30-Year analysis of trends and disparities across regions and Demographics

Body-Mass Index and All-Cause Mortality: Individual-Participant-Data Meta-Analysis of 239 Prospective Studies in Four Continents

The global burden of disease attributable to high body mass index in 204 countries and territories: Findings from 1990 to 2019 and predictions to 2035

The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021

Global Disease Burden Attributable to High Body Mass Index in Young Adults From 1990 to 2019, With Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2019

Global burden of cancer attributable to high body-mass index in 2012: a population-based study

The global death and disability burden associated with a high BMI in children and adolescents, 1990–2019

Global burden of noncommunicable disease attributable to high body mass index in 195 countries and territories, 1990-2017

The global burden of type 2 diabetes attributable to high body mass index in 204 countries and territories, 1990–2019: An analysis of the Global Burden of Disease Study

Delayed Effects of Obese and Overweight Population Conditions on All-Cause Adult Mortality Rate in the USA

Obesity and Cardiovascular Disease

Abstract 11459: The Biochemical and Physiological Pathways From Obesity to Cardiovascular Disease: A Prospective Cohort Study of 404332 UK Biobank Participants

The Relationship Between Excess Body Weight and the Risk of Death from Unnatural Causes.

Abstract WMP101: Global Burden of Stroke Attributable to High BMI in 38 OECD Countries From 1990-2019: A Benchmarking Systematic Analysis

Health and Economic Outcomes Associated With Musculoskeletal Disorders Attributable to High Body Mass Index in 192 Countries and Territories in 2019